The Radiochemistry and Molecular Imaging Probes (RMIP) Core Facility functions at the Intersection of the Cancer Center's laboratory research and clinical molecular Imaging initiatives - including cancer biology, medicine, chemistry, physics, radiochemistry, pharmacology and engineering, and is the largest manufacturing unit at MSKCC in terms of the number of clinical and research products produced. The RMIP Core Facility was established to provide investigators with radionuclides and to incorporate these radionuclides into radiolabeled diagnostic and/or therapeutic pharmaceuticals for both basic research investigations and patient formulations. The RMIP Core Facility consists of three major elements working closely together to provide the following services: (a) The Cyclotron Unit. Our MSKCC EBCO cyclotron on 72nd street produces 18F, 1241, 86Y and 89Zr, positron emitting radionuclides for research and clinical applications;(b) The Small Molecule Radiochemistry Section. This section incorporates cyclotron-produced positron-emitting radionuclides into radiochemicals and radiopharmaceuticals;(c) The Antibody Labeling Section. This section is responsible for the radiolabeling of peptides and monoclonal antibodies as requested by preclinical and clinical investigators for both cancer diagnostic and therapeutic purposes. MSKCC and the RMIP Core Facility have an outstanding reputation as a center for clinical translation of both imaging and therapeutic agents. Specifically, with regard to the translation of radiopharmaceuticals, over the past 20 years, the RMIP Core Facility has translated 37 radiopharmaceuticals for research clinical trials (imaging and therapy) in humans with radiolabeled antibodies, small molecules, nanoparticles and radiotherapeutics. To meet the growing programmatic demands and new federal regulations, MSKCC has implemented a significant investment In our radiochemistry facilities (to include GMP environments) over the next five years. The services provided by the RMIP Core have supported the research of 26 investigators in the past year. During the past grant period the work of the Core has contributed to 174 publications of researchers from 5 research programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA008748-48
Application #
8933547
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
2014-01-01
Project End
2018-12-31
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
48
Fiscal Year
2014
Total Cost
$357,996
Indirect Cost
$156,535
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Orlow, I; Satagopan, J M; Berwick, M et al. (2015) Genetic factors associated with naevus count and dermoscopic patterns: preliminary results from the Study of Nevi in Children (SONIC). Br J Dermatol 172:1081-9
Carey, Bryce W; Finley, Lydia W S; Cross, Justin R et al. (2015) Intracellular ?-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature 518:413-6
Mosher, C E; Given, B A; Ostroff, J S (2015) Barriers to mental health service use among distressed family caregivers of lung cancer patients. Eur J Cancer Care (Engl) 24:50-9
Navi, Babak B; Reiner, Anne S; Kamel, Hooman et al. (2015) Association between incident cancer and subsequent stroke. Ann Neurol 77:291-300
Xu, Zhe; Wu, Chaochao; Xie, Fang et al. (2015) Comprehensive quantitative analysis of ovarian and breast cancer tumor peptidomes. J Proteome Res 14:422-33
Xu, Hong; Cheng, Ming; Guo, Hongfen et al. (2015) Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody. Cancer Immunol Res 3:266-77
Gondo, Tatsuo; Poon, Bing Ying; Matsumoto, Kazuhiro et al. (2015) Clinical role of pathological downgrading after radical prostatectomy in patients with biopsy confirmed Gleason score 3 + 4 prostate cancer. BJU Int 115:81-6
Ye, Jiangbin; Fan, Jing; Venneti, Sriram et al. (2014) Serine catabolism regulates mitochondrial redox control during hypoxia. Cancer Discov 4:1406-17
Lu, Zhigang; Xu, Jin; Xu, Mingming et al. (2014) Morphine regulates expression of *-opioid receptor MOR-1A, an intron-retention carboxyl terminal splice variant of the *-opioid receptor (OPRM1) gene via miR-103/miR-107. Mol Pharmacol 85:368-80
Kaittanis, Charalambos; Shaffer, Travis M; Thorek, Daniel L J et al. (2014) Dawn of advanced molecular medicine: nanotechnological advancements in cancer imaging and therapy. Crit Rev Oncog 19:143-76

Showing the most recent 10 out of 836 publications